Working… Menu

Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression (CLL12)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02863718
Recruitment Status : Active, not recruiting
First Posted : August 11, 2016
Last Update Posted : June 7, 2019
Janssen-Cilag Ltd.
Information provided by (Responsible Party):
German CLL Study Group

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : March 7, 2019
Estimated Study Completion Date : April 2022